Residual Peripheral Blood CD26(+) Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission

Chronic myeloid leukemia (CML) patients in sustained “deep molecular response” may stop TKI treatment without disease recurrence; however, half of them lose molecular response shortly after TKI withdrawing. Well-defined eligibility criteria to predict a safe discontinuation up-front are still missin...

Descripción completa

Detalles Bibliográficos
Autores principales: Bocchia, Monica, Sicuranza, Anna, Abruzzese, Elisabetta, Iurlo, Alessandra, Sirianni, Santina, Gozzini, Antonella, Galimberti, Sara, Aprile, Lara, Martino, Bruno, Pregno, Patrizia, Sorà, Federica, Alunni, Giulia, Fava, Carmen, Castagnetti, Fausto, Puccetti, Luca, Breccia, Massimo, Cattaneo, Daniele, Defina, Marzia, Mulas, Olga, Baratè, Claudia, Caocci, Giovanni, Sica, Simona, Gozzetti, Alessandro, Luciano, Luigiana, Crugnola, Monica, Annunziata, Mario, Tiribelli, Mario, Pacelli, Paola, Ferrigno, Ilaria, Usala, Emilio, Sgherza, Nicola, Rosti, Gianantonio, Bosi, Alberto, Raspadori, Donatella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5988870/
https://www.ncbi.nlm.nih.gov/pubmed/29900128
http://dx.doi.org/10.3389/fonc.2018.00194

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5988870/
https://www.ncbi.nlm.nih.gov/pubmed/29900128
http://dx.doi.org/10.3389/fonc.2018.00194

Ejemplares similares